Full Press Release Details
to Exhibit at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13,
Management to discuss the benefits of Hemodiafiltration therapy and Quality
Life for End-Stage Renal Disease Patients
NY - May 13, 2008. Nephros, Inc., a medical device company developing and
marketing products designed to improve the quality of life for the End-Stage
Renal Disease (ESRD) patient, while addressing the critical financial and
clinical needs of the care provider, today announced that it will be exhibiting
at the XLV ERA-EDTA Congress in Stockholm, Sweden.
studies have demonstrated reductions of up to 35% in mortality risk using
hemodiafiltration (HDF) therapy in place of other standard hemodialysis
therapies. Additionally, reductions in drug requirements, lower morbidity
lower infection rates have been demonstrated in a range of studies substituting
hemodiafiltration for hemodialysis.
Nephros HDF system is designed to remove a range of harmful substances more
effectively and more cost-effectively than existing ESRD treatment methods,
particularly with respect to substances known collectively as "middle
molecules." These molecules have been found to contribute to such conditions
dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease
and, ultimately, mortality in the ESRD patient. Nephros's OLpur MD and H2H
technologies are currently in pre-approval clinical trials in the
HDF technology represents a new standard of therapy for ESRD patients," said
Norman J. Barta, Chairman and CEO of Nephros.. "Our OLpur MD hemodiafilter
series and our H2H module technologies are designed to provide a cost-effective
and user-friendly means for hospitals and clinics to upgrade to mid-dilution
therapy without replacing their current dialysis machines." The Stockholm
Congress will include technical presentations addressing various clinical
performance advantages of Nephros mid-dilution HDF therapy.
Inc., headquartered in New York, is a medical device company developing and
marketing products designed to improve the quality of life for the End-Stage
Renal Disease (ESRD) patient, while addressing the critical financial and
clinical needs of the care provider. ESRD is a disease state characterized
the irreversible loss of kidney function. Nephros products are sold and
distributed throughout Europe and are currently being used in over fifty
also markets a line of water filtration products, the Dual Stage Ultrafilter
(DSU) that produces biologically safe water. The Company's patented dual stage
cold sterilization Ultrafilter has the capability to filter out bacteria
due to its exceptional filtration levels, filter out many viruses and parasites.
The DSU is in a pilot-use program at a major U.S. medical center and has
selected for further development by the U.S. Marine Corps.
information on Nephros please visit the Company's website, www.nephros.com.
release contains certain "forward-looking statements" within the meaning
Private Securities Litigation Reform Act of 1995, as amended. Such statements
include statements regarding the efficacy and intended use of the Nephros's
technologies under development, the timelines for bringing such products
market and the availability of funding sources for continued development
products and other statements that are not historical facts, including
statements which may be preceded by the words "intends," "may," "will," "plans,"
"expects," "anticipates," "projects," "predicts," "estimates," "aims,"
"believes," "hopes," "potential" or similar words. For such statements, Nephros
claims the protection of the Private Securities Litigation Reform Act of
statements are not guarantees of future performance, are based on certain
assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond Nephros's control. Actual results
differ materially from the expectations contained in the forward-looking
statements. Factors that may cause such differences include the risks that:
Nephros may not be able to obtain funding if and when needed or on terms
favorable to it in order to continue operations or fund its clinical trials;
(ii) Nephros may not be able to continue as a going concern; (iii) Nephros
not be able to liquidate its short-term investments when needed to fund its
operations; (iv) Nephros may be unable to maintain compliance with the American
Stock Exchange's continued listing standards; (v) products that appeared
promising to Nephros in research or clinical trials may not demonstrate
anticipated efficacy, safety or cost savings in subsequent pre-clinical or
clinical trials; (vi) Nephros may not obtain appropriate or necessary
governmental approvals to achieve its business plan or effectively market
products; (vii) Nephros may encounter unanticipated internal control
deficiencies or weaknesses or ineffective disclosure controls and procedures;
(viii) HDF therapy may not be accepted in the United States and/or Nephros'
technology and products may not be accepted in current or future target markets,
which could lead to failure to achieve market penetration of Nephros' products;
(ix) Nephros may not be able to sell its ESRD therapy or water filtration
products at competitive prices or profitably; and (x) Nephros may not be
secure or enforce adequate legal protection, including patent protection,
its products. More detailed information about Nephros and the risk factors
may affect the realization of forward-looking statements is set forth in
Nephros' filings with the Securities and Exchange Commission, including Nephros'
Annual Report on Form 10-KSB filed with the SEC for the fiscal year ended
December 31, 2007. Investors and security holders are urged to read these
documents free of charge on the SEC's web site at www.sec.gov. Nephros does
undertake to publicly update or revise its forward-looking statements as
result of new information, future events or otherwise.